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Abstract
Aim: The present study aimed to evaluate the change in quality of life 12 months following liver transplantation in patients with Familial Amyloid
Polyneuropathy (FAP).
Method: In this study 150 transplant candidates, attending the outpatient clinic of a Liver Transplantation Centre in Lisbon, were assessed
between March 1, 2006 and December 1, 2007. From these, 84 were transplanted, and 62 finished the study; 20 with FAP and 42 with Liver
Disease (LD). These patients were assessed before, and 12 months after, transplantation. The patients that remained waiting for transplantation
originated the control group. First, transplanted (study group) and non-transplanted (control group) patients were compared regardless of their
diagnosis, and then only FAP patients were compared between both groups.
Results: 12 months after transplantation the score on the Quality of Life’s Physical and Mental Component of the SF-36 was significantly
higher in transplanted versus non-transplanted patients (concerning the whole group FAP and LD patients). However, significant differences
were only found for the Quality of Life’s Physical Component subscale between both FAP groups (study and control group).
Conclusion: In sum, liver transplantation does not have a significant impact in FAP patients’ Mental Quality of Life score. One possible reason
to this is the fail in acquiring adaptive coping strategies after transplantation.
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Introduction
Familial amyloid polyneuropathy (FAP) is an autosomal dominant multisystemic fatal disorder characterized by
a progressive peripheral and autonomic neuropathy with neural and systemic amyloid deposits (Monteiro, Freire,
& Barroso, 2004). The amyloid protein in type 1 FAP of Portuguese, Swedish and Japanese origin, is the variant
of transthyretin (TTR), in which methionine a substitute for valine at position 30 is (TTR Met). Most of this TTR
Met 30 is produced by the liver. The most consensual way to treat FAP is liver transplantation in the initial stage
of the disease, to prevent neurological deterioration.
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didates that usually have a disabling chronic liver disease (Monteiro et al., 2004). It has been demonstrated that
quality of life (QoL) can be improved after transplantation in patients with liver disease (Monteiro et al., 2004; Price
et al., 1995; Riether, Smith, Lewison, Cotsonis, & Epstein, 1992; Telles-Correia, Barbosa, Mega, & Monteiro,
2008). To our best knowledge, no other study was conducted besides by our group that evaluates QoL improvement
in FAP patients. Nevertheless, this was done by comparing QoL 6 months after transplantation in patients with
FAP and those with chronic liver disease (Telles-Correia, Cortez-Pinto, Barbosa, Mega, & Monteiro, 2009).
The aim of the present prospective study was to evaluate the change in quality of life 12 months after liver trans-
plantation in patients with FAP. This was accomplished using a group of non-transplanted FAP patients as control
group.
Method
Participants
A group of 150 transplant candidates, attending the outpatient clinic of Liver Transplantation Centre in Lisbon,
were studied between March 1, 2006 and December 1, 2007. From these, 84 were transplanted.
These patients were assessed twice (the first time before transplantation and the second time 12 months after
transplantation). Within the transplanted group, 11 patients died, three were retransplanted (thus, excluded from
the study), and eight withdrew from the study. A total of 62 transplanted patients finished the study (study group).
The patients that remained waiting for transplantation originated the control group.
Written informed consent was obtained from all participants, and the study protocol was approved by the Curry
Cabral Hospital’s Ethical Committee.
Regarding medical diagnosis, within the study group, 20 patients had FAP and 42 had chronic liver disease (CLD).
Among the patients with liver disease, 16 had Alcohol-related Liver Disease (ALD), six Hepatitis C and Associated
Cirrhosis (HCAC), one Hepatocellular Carcinoma (HCC), one Primary Biliary Cirrhosis (PBC), one Progressive
Familial Intrahepatic Cholestasis (PIC), one Sclerosing Cholangitis, one Cryptogenic Cirrhosis (CC), and the re-
maining had Mixed Diagnoses (11 ALD + HCC; seven HCAC + HCC; three HCAC + HCC + ALD; one HCC +
Virus B Liver Disease; one Hemochromatosis + HCC), three unknown cause. Within the control group 15 patients
had FAP and 25 had CLD. Among the patients with CLD, 11 had ALD, two HCAC, two PBC, one PIC, one CC,
and the others had Mixed Diagnosis (six ALD + HCC; seven HCAC + B Hepatitis.
Within the study group, in the CLD subgroup, 18 patients were classified Child-Pugh class A (see Medical evaluation
chapter for the explanation of this classification), 22 class B and six class C. In the FAP subgroup ten patients
were classified as Level 1 FAP, eight Level 2 and two Level 3. Within the control group, in the CLD subgroup, ten
patients were classified Child-Pugh class A, 11 class B and four class C. In the FAP subgroup, Nine patients were
classified as Level 1 FAP, five Level 2 and one Level 3.
In the study group 40 patients were male, and the mean age was 45.40 (SD = 12.22). In the control group, 24
patients were male and the mean age was 47.20 (SD = 13.33). No significant differences regarding demographic
and medical data were found between both groups.
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Quality of Life — We used the MOS 36-Item Short Form Survey Instrument (SF-36; Ware, 1993). Portuguese
validated version (Pais-Ribeiro, 1993), a self-rating questionnaire developed by the Medical Outcome Trust (Ware,
1993), to assess quality of life. The SF-36 has been widely used under a range of different medical conditions
and shown to have adequate reliability and validity. The first four subscales refer to physical aspects, and the last
four scales, mental aspects: physical functioning, physical role Limitation, bodily pain, general health, vitality, social
functioning, emotional role limitation and emotional well-being. Physical aspects mostly refer to physical capability
to perform normal daily activities. The mental dimension mostly refers to social aspects of life the degree to which
illness interferes with emotional well-being, and social roles. Total values were computed for physical and mental
components of health-related quality of life by averaging the eight weighted subscales.
Medical Evaluation — The diagnosis of chronic liver disease (CLD) was established by a hepathologist. Child-
Pugh classification was used to evaluate liver disease severity. It is based on a patient’s bilirubin and albumin
serum levels, the international normalized ratio (INR) (a measure of coagulation) and the presence or absence
of ascites and encephalopathy. Patients belonging to class A are the ones with best prognosis and the ones be-
longing to class C have the worst prognosis.
The diagnosis of FAP was established by a neurologist. To evaluate the severity of FAP the (REF) (Sales-Luís,
Galvão, Sousa, Alves, & Serrão, 1990) Portuguese classification was used. This scale considers six levels of
severity: Level 0 – asymptomatic; Level 1 – sensitive and/or dysautonomic symptoms without neurological signs;
Level 2 – sensitive and/or dysautonomic symptoms + neurological signs (sensitive); Level 3 – sensitive and/or
dysautonomic symptoms + neurological signs (sensitive-motor) in lower limbs with independent walking; Level 4
– neurological signs in lower and upper limbs (sensitive or motor) walking without help; Level 5 – neurological
signs (sensitive or motor) in lower and upper limbs, in wheel chair; Level 6 – confined to bed.
Procedure
Patients from the study group (transplanted patients) were assessed twice: the first time before transplantation
and the second time 12 months after transplantation. The ones that remained waiting for transplantation originated
the control group.
Firstly, transplanted (study group) and non-transplanted (control group) patients were compared regardless of
their diagnosis, and then only FAP patients were compared between both groups.
Statistical Analysis
Statistical analyses were performed with the SPSS 13.0 for Windows software package. Descriptive data were
presented in absolute frequencies, percentages, mean values, standard deviations, and modes. QL differences
between groups were assessed by means of the Mann Whitney test (a p < .05 was considered statistically signi-
ficant).
Results
Quality of Life Differences
First, we looked for the differences between the study group and the control group within the whole sample. We
found that before transplantation there were no differences between the groups. Quality of Life’s Physical and
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FAP patients, before transplantation there were no differences between the study group and the control group.
After transplantation we still did not find significant differences for Quality of Life’s Mental Component, though we
did for Quality of Life’s Physical Component (Table 2).
Table 1
QoL in the Total Sample 12 Months After Transplantation – Differences Between the Study Group (FAP + LD) and the Control Group (FAP
+ LD)
p W U Control Group (FAP+LD) Study Group (FAP+LD) QoL
Physical component .001 .00 887 .00 359 .15 43 .29 68
Mental component .008 .00 922 .00 361 .63 55 .12 70
Table 2
QoL in the FAP Subgroup 12 Months After Transplantation – Differences Between the Study Group and the Control Group
p W U Control Group (FAP) Study Group (FAP) QoL
Physical component .010 .00 320 .00 110 .00 43 .25 65
Mental component .800 .00 720 .00 430 .00 61 .50 68
Discussion
Several authors found an improvement in mental and physical quality of life components after liver transplantation
(Price et al., 1995; Riether et al., 1992). However, most of them evaluated decompensated liver disease patients,
and not special groups, such as FAP patients. To our knowledge, this is the first study evaluating mental and
physical quality of life in FAP patients 12 months after liver transplantation, using non-transplanted FAP patients
as a control group. FAP patients have a genetic disease, invariably fatal without treatment, and are now being
transplanted at a very early stage, with a paucity of symptoms, and therefore a very special group.
Telles-Correia and colleagues (2008) found that there was a high prevalence of psychiatric diagnoses (mostly
depression and anxiety) in familial amyloid polyneuropathy patients waiting for transplantation and that these
patients had a different personality profile comparing to other liver transplant candidates. This might be due to
the emotional stress of being exposed to a chronic sensation of being carrier of a fatal genetic disease (Telles-
Correia et al., 2008)
The fact that liver transplantation had a less beneficial impact in the mental quality of life of FAP patients is difficult
to explain. One possible reason to this is the failure in acquiring adaptive coping strategies after transplantation.
Telles-Correia, found that these patients could develop unadaptive coping styles after transplantation because of
a poor familiarity with acute medical symptoms and due to unrealistic expectations towards liver transplantation
(Telles-Correia, 2013). According to Moos and Schaefer’s (1993) model, coping strategies can predict mental
health and quality of life (Telles-Correia, 2013), and this might be an explanation for our conclusions, concerning
FAP patients’ quality of life after liver transplantation. These hypotheses must be confirmed by further studies.
Psychology, Community & Health
2014, Vol. 3(2), 73–78
doi:10.5964/pch.v3i2.60
Quality of Life Following Liver Transplantation 76Based on our findings, special groups such as FAP patients should be followed up with special attention since
they may be more vulnerable in terms of mental health and quality of life.
One of the main limitations of the present study is the small number of FAP patients included, which relates to
the difficulty of conducting a prospective study in such a rare disease. More studies in this area are needed to
confirm our findings and further explore our knowledge about FAP patients’ psychological profile, in order to design
specific strategies that can improve their quality of life after liver transplantation.
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